Australia · Delayed Price · Currency is AUD Sonic Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 5% organically in H1 FY2026, with EBITDA margin up 30 bps and net profit at AUD 262 million. Guidance for FY2026 EBITDA is reaffirmed, with margin expansion in Germany and Switzerland, and ongoing cost control and capital management initiatives.
Fiscal Year 2025
-
The meeting marked a major leadership transition, reviewed strong financial growth, and reaffirmed strategic focus on organic expansion, acquisitions, and sustainability. Shareholders approved all resolutions and discussed challenges such as regulatory risk, labor costs, and earnings growth.
-
Revenue and EBITDA both grew 8% year-over-year, with strong cash generation and margin expansion. FY 2026 guidance anticipates up to 19% EPS growth, driven by organic growth and recent acquisitions, while integration and synergy capture are underway across key geographies.
-
Strong half-year results with 8% revenue and 17% net profit growth, driven by organic expansion, cost control, and recent acquisitions. Margin expansion and robust cash flow support positive guidance, with major synergies expected from the Kramer Group acquisition and ongoing operational improvements.
Fiscal Year 2024
-
The AGM highlighted strong base business growth, major acquisitions, and ongoing margin recovery efforts amid post-COVID challenges. Board renewal, sustainability, and AI-driven innovation were emphasized, with all resolutions passed and a progressive dividend increase announced.
-
FY 2024 saw strong organic growth, major acquisitions, and a return to margin expansion, with EBITDA of AUD 1.602 billion and a 2% dividend increase. Guidance for FY 2025 targets up to 10% EBITDA growth, supported by easing inflation and integration of recent acquisitions.